Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
Activation of GLP-1 and GIP receptors also leads to nonglycemic effects in multiple tissues, through direct actions on tissues expressing incretin receptors and indirect mechanisms mediated through neuronal and endocrine pathways .
Incretin -based therapies—including GLP-1 receptor agonists and DPP-4 inhibitors—demonstrate significant benefits in glycemic control, though limitations such as β-cell resistance and modest cardiovascular outcomes in some agents persist. Dual receptor agonists like tirzepatide show improved metabolic effects .
The Roles of Incretin Hormones GIP and GLP
Abstract The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 ( GLP-1 ) play central roles in metabolic and cardiovascular regulation. GLP-1 receptor agonists ( GLP -1RAs) are established therapies for type 2 diabetes mellitus (T2DM) and obesity because of their insulinotropic effects , weight reduction, and proven cardiovascular benefit in trial ...

The physiological roles of endogenously secreted incretins (ie, GLP-1 and glucose-dependent insulinotropic peptide [GIP]), including vasodilation and mild inotropic effects , link digestion to metabolism by enhancing nutrient absorption, delivery, and use. These mechanisms seamlessly contribute to cardiovascular protection when applied therapeutically (ie, using GLP-1 receptor and GIP receptor ...
The Roles of Incretin Hormones GIP and GLP
The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 ( GLP-1 ) play central roles in metabolic and cardiovascular regulation. GLP-1 receptor agonists ( GLP -1RAs) are established therapies for type 2 diabetes mellitus (T2DM) and obesity because of their insulinotropic effects , weight reduction, and proven cardiovascular benefit in trial level. In ...
Overview of Glp-1 And Incretin Effect Pathways

As we can see from the illustration, Glp 1 And Incretin Effect Pathways has many fascinating aspects to explore.
GLP-1 receptor agonists were initially developed to treat type 2 diabetes and have had a transformative effect on its therapy, and are highly effective for glycaemic control, with the added benefit of bodyweight reduction and a low risk of causing hypoglycaemia. GLP-1 receptor agonists reduce risks for major adverse cardiovascular events (eg, non-fatal myocardial infarction, stroke, and ...
Gastrointestinal hormones that potentiate insulin secretion from pancreatic β-cells are called incretins . Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 ( GLP-1 ) are the major incretins . Incretin -mediated stimulation of insulin secretion ( incretin effect ) plays an important role in lowering postprandial blood-glucose levels ...
Integrative gene
Glucagon-like peptide-1 ( GLP-1 ) is an incretin hormone, secreted by intestinal L-cells, with levels rising after nutrient intake. When nutrient levels increase, the secretion of GLP-1 intensifies ...
Glucagon-like peptide-1 ( GLP-1 ) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ago...